Lu 177 dotatate therapy

Displaying 4 studies

  • EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL

    Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to allow patients suffering from inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy to access the investigational product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.

  • Diagnostic 68Ga-PSMA-11 PET/CT Rochester, MN

    The purpose of this study is the diagnostic 68Ga-PSMA-11 PET/CT imaging for screening prior to consideration of 177Lu-PSMA-617 therapy.

  • A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL

    The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients.

  • A Study of Lutetium Lu 177 Dotatate (Lutathera®) in Patients with Inoperable, Progressive Meningioma after External Beam Radiation Therapy Rochester, MN

    The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6-month PFS rate, and to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 2 or 3 meningioma as measured by 6-month PFS rate.

     

.

Mayo Clinic Footer